Abstract
The aetiology of essential hypertension, a disease prevalent in cultured societies, is unknown. However, much evidence suggests that abnormal sodium metabolism has a critical role—this has led to the hypothesis that an increase in the circulating concentration of an inhibitor of (Na+ + K+) ATPase is responsible for the increased peripheral vascular resistance in essential hypertension1. Evidence for relatively high levels of a Na+ pump inhibitor in essential hypertension has come from bioassay and cytochemical assays of plasma and urine from normotensive and hypertensive individuals2,3. There is also evidence for increased plasma levels of a Na+ pump inhibitor in some animal models (for example, renal and deoxycorticosterone acetate (DOCA) models) of hypertension4. Nevertheless, direct biochemical determination of (Na+ + K+) ATPase inhibition by this substance has not yet been reported. We demonstrate here, with a kinetic (Na+ + K+) ATPase assay, a highly significant correlation between levels of a plasma inhibitor of (Na+ + K+)ATPase activity and mean arterial blood pressure (MAP) in normotensive and hypertensive individuals. These data provide evidence for the involvement of a circulating Na+ pump inhibitor in the genesis of essential hypertension. Moreover, our assay methods may be useful for the isolation and characterization of this inhibitor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blaustein, M. P. Am. J. Physiol. 232, C165–C173 (1977).
MacGregor, G. A. et al. Br. med. J. 283, 1335–1357 (1981).
Poston, L. et al. Br. med. J. 282, 847–849 (1981).
Pamnani, M. B., Huot, S., Buggy, J., Clough, D. & Haddy, F. Hypertension 3, Suppl. Ii, II-96–Ii-101 (1981).
Akera, T., Choi, Y. R. & Yamamoto, S. in Na, K-ATPase, Structure and Kinetics (eds Skou, J. C. & Norby, J. G.) 405–420 (Academic, New York, 1979).
Fagan, J. B. & Racker, E. Biochemistry 16, 152–158 (1977).
Quist, E. E. & Hokin, L. E. Biochim. biophys. Acta 511, 202–212 (1978).
Cantley, L. C. et al. J. biol Chem. 252, 7421–7423 (1977).
Jorgensen, P. L. Biochim. biophys. Acta 356, 36–52 (1974).
Gruber, K. A., Whitaker, J. M. & Buckalew, V. M. Nature 287, 743–745 (1980).
Gruber, K. A., Rudel, L. L. & Bullock, B. C. Hypertension 4, 348–354 (1982).
Losse, H., Wehmeyer, H. & Wessels, F. Klin. Wschr. 38, 393–395 (1960).
Edmondson, R. P. S., Thomas, R. D., Hilton, P. J., Patrick, J. & Jones, N. F. Lancet i, 1003–1005 (1975).
Blaustein, M. P. Clin. exp. Hypertension 3, 173–178 (1981).
Blaustein, M. P. in Recent Advances in Hypertension Mechanisms (eds Villareal, H. & Sambhi, M.) (in the press).
Lang, S. & Blaustein, M. P. Circulation Res. 46, 463–470 (1980).
Filo, R. S., Bohr, D. F. & Rüegg, J. C. Science 147, 1581–1583 (1972).
Folkow, B. & Neil, E. Circulation, 560–583 (Oxford University Press, 1971).
Nakazato, Y., Ohga, A. & Onoda, Y. J. Physiol., Land. 278, 45–54 (1978).
Leitz, F. H. & Stefano, F. J. E. Eur. J. Pharmac. 11, 278–285 (1970).
de Wardener, H. E. & MacGregor, G. A. Kidney Int. 18, 1–9 (1980).
de Wardener, H. E. Am. J. Physiol. 235, F163–F173 (1978).
Zadik, Z., Hamilton, B. P. & Kowarski, A. A. J. clin Endocr. Metab. 50, 842–845 (1980).
Kowarski, A. A., Edwin, C. J., Akesode, A. P., Pitrowski, L. S. & Hamilton, B. P. Johns Hopkins med. J. 142, 35–38 (1978).
King, E. J. Biochem. J. 26, 292–297 (1932).
Bradford, M. M. Analyt. Biochem. 72, 248–254 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hamlyn, J., Ringel, R., Schaeffer, J. et al. A circulating inhibitor of (Na+ + K+) ATPase associated with essential hypertension. Nature 300, 650–652 (1982). https://doi.org/10.1038/300650a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/300650a0
This article is cited by
-
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Signal Transduction and Targeted Therapy (2023)
-
The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin–angiotensin–aldosterone system, oxidative stress and endogenous digitalis in the brain
Hypertension Research (2011)
-
Endogenous digitalis: pathophysiologic roles and therapeutic applications
Nature Clinical Practice Nephrology (2008)
-
Hypertension, Na+/Ca2+ exchanger, and Na+, K+-ATPase
Kidney International (2006)
-
Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle
Nature Medicine (2004)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.